Pfizer Inc. is navigating financial turbulence, highlighted by a 40% year-over-year decline in COVID-19 product revenues and anticipated revenue compression of $1.5 billion in 2026 due to generic entries. Despite reporting stronger-than-expected earnings of 66 cents per share, investor concerns have led to stock declines. Looking ahead, Pfizer is strategically entering the competitive obesity market, eyeing a $100 billion opportunity, while also committing to a catalyst-rich year in 2026 with key clinical data expected to drive future growth.
“In obesity, Pfizer is entering a space largely dominated by Novo Nordisk and Eli Lilly. NVO and LLY already market GLP-1 drugs that have shown strong efficacy and gained significant market share. In addition, others like Viking Therapeutics, Amgen and Structure Therapeutics are also developing novel obesity candidates in late-stage studies, which means the market is extremely competitive. Nonetheless, the obesity market is huge with a $100 billion + opportunity.”
“President Trump formally launched the TrumpRx program on Thursday evening. Initially, discounts are available for 43 drugs from five drugmakers: AstraZeneca (AZN), Eli Lilly (LLY), EMD Serono, Novo Nordisk (NVO), and Pfizer (PFE).”
“Pfizer remains on the cutting edge of pharmaceutical science and strives to stay ahead of medical trends with continuous research and development. ... Pfizer's fourth-quarter 2025 adjusted income grew 5% year over year to $3.786 billion.”
“Furthermore, it's encouraging to discover that Pfizer has a 15-year track record of dividend growth.”
“It's encouraging to discover that Pfizer currently offers a forward annual dividend yield of 6.49%.”
“Like PFE and HPQ, VZ stock can add stability to your portfolio as these assets tend to gain value over the long term.”
“Pfizer expects 2026 to be a catalyst-rich year, with some key data-readouts expected in the obesity and oncology programs.”
“From a valuation standpoint, Pfizer appears attractive relative to the industry and is trading below its 5-year mean. Going by the price/earnings ratio, the company’s shares currently trade at 8.98 forward earnings, lower than 18.85 for the industry and the stock’s 5-year mean of 10.24.”
“In 2025, the emphasis will move to improving R&D productivity... we believe we have a strong year of catalysts ahead of us and expect our new R&D organization to achieve multiple key milestones, including the possibility of at least four regulatory decisions, up to nine potential Phase 3 readouts and 13 potential pivotal program starts.”
“Eliquis is a core brand for Pfizer with 10% worldwide year-over-year operational growth.”
“We are also pleased with the ongoing positive momentum for Nurtec with 36% worldwide year-over-year operational growth.”
“we're now targeting first quarter to have data from the ongoing dose optimization and formulation study, the PK study, and we're on track to deliver that in Q1.”
.svg&width=160)